Tom Nolan reviews this week’s research Established surgical treatment for people with severe aortic stenosis who have obstructive coronary artery disease is surgical aortic valve replacement (SAVR) ...

U.S. approval of an expanded indication for transcatheter aortic valve replacement in patients without symptoms is among the ...

At its investor day conference, Edwards Lifesciences Corp. prognosticated that an expanded indication in transcatheter aortic ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) and reminds investors ...

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities ...

The global Structural Heart Devices market is expected to grow to USD 25.69 Billion by 2029, up from USD 16.31 Billion in ...

Capstan Medical has reeled in $110 million to continue its mission of bringing robotic surgery to a previously untouched ...

Edwards Lifesciences Investors have Until Tomorrow December 13 before Expiration of Court Deadline - Contact BFA Law ...

Capstan Medical, which is developing heart valve implants with a robotic delivery platform, said Wednesday it has secured ...

Edwards Lifesciences outlines 2025 growth strategy, emphasizing innovations in TAVR and TMTT therapies, with a projected ...

Anteris Technologies today announced the launch of its initial public offering in the U.S. to advance the development of its ...

Notable examples include the SAPIEN 3 Ultra Transcatheter Heart Valve, a leading device in transcatheter aortic valve replacement (TAVR) known for its durability and enhanced sealing capabilities, and ...